EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Comparison of the efficacy of cisplatin and carboplatin in combination with etoposide in firstline treatment of extensive-stage small cell lung cancer in real-world practice in the Czech Republic - a retrospective analysis of patients from the LUCAS project

Alzbeta Bejckova, Miloslav Marel, Zdenka Chladkova, Libor Fila, Luis Fernando Casas-Mendez, Ondrej Venclicek, Petr Jakubec, Marketa Cernovska, Michal Hrnciarik, Jana Krejci, Petr Domecky, Martin Svaton

Biomedical Papers · 2025

DOI: 10.5507/bp.2024.019 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Biomedical Papers, 2025. Verfasst von Alzbeta Bejckova und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic. Hauptthemen laut MEDLINE: Etoposide, Carboplatin, Cisplatin, Lung Neoplasms. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Patients with extensive-stage small-cell lung cancer (ES-SCLC) have a poor prognosis. The standard palliative treatment for four decades has been chemotherapy as a combination of etoposide with carboplatin or cisplatin, and in recent years, immunotherapy in addition. AIMS: To determine whether there is a difference in the efficacy of palliative chemotherapy as cisplatin or carboplatin in combination with etoposide in patients with ES-SCLC in real-world practice in the Czech Republic. METHODS: This was a retrospective analysis of a cohort of 348 patients from the LUCAS project with ES-SCLC. 79 were treated with etoposide plus cisplatin and 265 were treated with etoposide plus carboplatin. Kaplan-Meier curves and the Cox regression model were used for analysis. RESULTS: No statistically significant difference in median overall survival (mOS) or median progression free survival (mPFS) was found between groups or between patients grouped according to age and performance status (PS) in mOS. The Cox regression result was similar. CONCLUSION: This study shows that cisplatin and carboplatin do not differ in efficacy in a given indication, thus when choosing a treatment, the physician should consider the expected toxicity in a particular patient, assessing the patient's general condition and comorbidities.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EtoposideCarboplatinCisplatinLung NeoplasmsSmall Cell Lung CarcinomaAntineoplastic Combined Chemotherapy ProtocolsHumansRetrospective StudiesFemaleMaleMiddle AgedAgedCzech RepublicAdultTreatment OutcomeAged, 80 and over

Stichwörter der Autor:innen

carboplatincisplatinextensive-stagesmall cell lung cancer

Substanzen

EtoposideCarboplatinCisplatin

Autor:innen und Institutionen

  • Department of Pulmonology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic.
  • Department of Respiratory Diseases, Faculty of Medicine, Masaryk University and University Hospital, Brno, Czech Republic.
  • Department of Respiratory Medicine, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic.
  • Department of Respiratory Medicine, Thomayer Hospital and 1st Faculty of Medicine, Charles University, Prague, Czech Republic.
  • Pulmonary Department, University Hospital Hradec Kralove and Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic.
  • Department of Pneumology, Bulovka University Hospital and 3rd Faculty of Medicine, Charles University, Prague, Czech Republic.

Zitieren

APA

Bejckova, A., Marel, M., Chladkova, Z., Fila, L., Casas-Mendez, L. F., Venclicek, O., Jakubec, P., Cernovska, M., Hrnciarik, M., Krejci, J., Domecky, P., & Svaton, M. (2025). Comparison of the efficacy of cisplatin and carboplatin in combination with etoposide in firstline treatment of extensive-stage small cell lung cancer in real-world practice in the Czech Republic - a retrospective analysis of patients from the LUCAS project. Biomedical Papers. https://doi.org/10.5507/bp.2024.019

Vancouver

Bejckova A, Marel M, Chladkova Z, Fila L, Casas-Mendez LF, Venclicek O, et al. Comparison of the efficacy of cisplatin and carboplatin in combination with etoposide in firstline treatment of extensive-stage small cell lung cancer in real-world practice in the Czech Republic - a retrospective analysis of patients from the LUCAS project. Biomedical Papers. 2025. doi:10.5507/bp.2024.019

BibTeX
@article{Bejckova2025,
  author = {Bejckova, Alzbeta and Marel, Miloslav and Chladkova, Zdenka and Fila, Libor and Casas-Mendez, Luis Fernando and Venclicek, Ondrej and Jakubec, Petr and Cernovska, Marketa and Hrnciarik, Michal and Krejci, Jana and Domecky, Petr and Svaton, Martin},
  title = {Comparison of the efficacy of cisplatin and carboplatin in combination with etoposide in firstline treatment of extensive-stage small cell lung cancer in real-world practice in the Czech Republic - a retrospective analysis of patients from the LUCAS project},
  journal = {Biomedical Papers},
  year = {2025},
  doi = {10.5507/bp.2024.019}
}
Kostenlos starten →